Schouwink H[au] - Search Results

Year	Number of Results
1989	1
1998	1
1999	2
2000	2
2001	2
2003	1
2004	1
2020	1
2021	0

1

Improving lung cancer diagnosis by combining exhaled-breath data and clinical parameters.

Kort S, Brusse-Keizer M, Gerritsen JW, Schouwink H, Citgez E, de Jongh F, van der Maten J, Samii S, van den Bogart M, van der Palen J. Kort S, et al. Among authors: schouwink h. ERJ Open Res. 2020 Mar 16;6(1):00221-2019. doi: 10.1183/23120541.00221-2019. eCollection 2020 Jan. ERJ Open Res. 2020. PMID: 32201682 Free PMC article.

2

Malignant pleural mesothelioma.

Baas P, Schouwink H, Zoetmulder FA. Baas P, et al. Among authors: schouwink h. Ann Oncol. 1998 Feb;9(2):139-49. doi: 10.1023/a:1008239116237. Ann Oncol. 1998. PMID: 9553658 Review. No abstract available.

3

Oxygen depletion during and after mTHPC-mediated photodynamic therapy in RIF1 and H-MESO1 tumors.

Schouwink H, Oppelaar H, Ruevekamp M, van der Valk M, Hart G, Rijken P, Baas P, Stewart FA. Schouwink H, et al. Radiat Res. 2003 Feb;159(2):190-8. doi: 10.1667/0033-7587(2003)159[0190:oddaam]2.0.co;2. Radiat Res. 2003. PMID: 12537524

4

Photodynamic therapy for malignant mesothelioma: preclinical studies for optimization of treatment protocols.

Schouwink H, Ruevekamp M, Oppelaar H, van Veen R, Baas P, Stewart FA. Schouwink H, et al. Photochem Photobiol. 2001 Apr;73(4):410-7. doi: 10.1562/0031-8655(2001)073<0410:ptfmmp>2.0.co;2. Photochem Photobiol. 2001. PMID: 11332037

5

Caelyx in malignant mesothelioma: a phase II EORTC study.

Baas P, van Meerbeeck J, Groen H, Schouwink H, Burgers S, Daamen S, Giaccone G. Baas P, et al. Among authors: schouwink h. Ann Oncol. 2000 Jun;11(6):697-700. doi: 10.1023/a:1008346925273. Ann Oncol. 2000. PMID: 10942058 Free article. Clinical Trial.

6

Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma.

Schouwink H, Korse CM, Bonfrer JM, Hart AA, Baas P. Schouwink H, et al. Lung Cancer. 1999 Jul;25(1):25-32. doi: 10.1016/s0169-5002(99)00044-6. Lung Cancer. 1999. PMID: 10466859

7

Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results.

Schouwink H, Rutgers ET, van der Sijp J, Oppelaar H, van Zandwijk N, van Veen R, Burgers S, Stewart FA, Zoetmulder F, Baas P. Schouwink H, et al. Chest. 2001 Oct;120(4):1167-74. doi: 10.1378/chest.120.4.1167. Chest. 2001. PMID: 11591556

8

Malignant pleural mesothelioma.

Schouwink H, Baas P, Rutgers ET, Zoetmulder FA. Schouwink H, et al. Eur Respir J. 1999 Mar;13(3):706. doi: 10.1183/09031936.99.13370699. Eur Respir J. 1999. PMID: 10232452 Free article. No abstract available.

9

Foscan-mediated photodynamic therapy and operation for malignant pleural mesothelioma.

Schouwink H, Baas P. Schouwink H, et al. Ann Thorac Surg. 2004 Jul;78(1):388; author reply 388-9. doi: 10.1016/j.athoracsur.2003.08.088. Ann Thorac Surg. 2004. PMID: 15223483 No abstract available.

10

Monitoring of impending myocardial damage after pleuropneumonectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma using biochemical markers.

Klaase JM, Swaanenburg JC, Schouwink H, Sosef MN, Bonfrer JM, Zoetmulder FA, Rutgers EJ, Baas P. Klaase JM, et al. Among authors: schouwink h. Photochem Photobiol. 2000 Mar;71(3):351-4. doi: 10.1562/0031-8655(2000)071<0351:moimda>2.0.co;2. Photochem Photobiol. 2000. PMID: 10732455

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results